Pharmacokinetics of etoposide with intravenous drug administration in children and adolescents

Pediatrics International - Tập 45 Số 1 - Trang 74-79 - 2003
Yasuhiro Kato1,2, Shin‐Ichiro Nishimura1, Nobuo Sakura1, Kazuhiro Ueda1
1Department of Pediatrics, Hiroshima University, School of Medicine, Hiroshima, Japan
2Department of Pediatrics, National Hiroshima Hospital, Higashi-Hiroshima,

Tóm tắt

Abstract Background : Pharmacokinetics of etoposide in Japanese children and adolescents has not been investigated. The objectives of the present study were (i) to document the pharmacokinetics of etoposide in Japanese children; (ii) to determine the intra‐ and interpatient variability in systemic etoposide exposure and (iii) to obtain insights into the age–pharmacokinetic parameter relationship. Methods : Pharmacokinetic studies of etoposide, given at doses of 60–200 mg/m2 by intravenous (i.v.) route of administration, were conducted in 18 children and adolescents (aged <19 years) with malignant diseases. High performance liquid chromatography was used to measure the blood etoposide levels. Results : Pharmacokinetic parameters (mean~SD) of the 14 patients (24 courses) who received etoposide 100 mg/m2 were as follows: peak serum concentration (Cmax), 18.5~6.4 μg/mL; trough serum concentration, 0.2~0.1 μg/mL; biological half‐life (T1/2), 3.6~0.7 h; volume of distribution (Vd), 6.3~3.4 L/m2; area under the etoposide serum concentration‐time curve (AUC), 129~38 hr•μg/mL; systemic clearance, 21.1~10.8 mL/min per m2. The T1/2, Vd, and AUC were not associated with age. An increase in etoposide dose per body surface area (BSA) was associated with increase in its Cmax and area under the time‐concentration curve (AUC). Wide interpatient variability in these parameters was demonstrated. Conclusion : The present study demonstrated that: (i) Pharmacokinetics of etoposide in Japanese children and adolescents were similar to those in Caucasians. (ii) Increased exposure to etoposide was associated with the Cmax. A clear correlation between Cmax and AUC was also found. (iii) Selecting the dose of etoposide according to body surface area (BSA) might give an acceptable range of exposure for children more than 1 year of age.

Từ khóa


Tài liệu tham khảo

10.1200/JCO.1994.12.7.1427

Lowis SP, 1993, Etoposide pharmacokinetics in children: The development and prospective validation of a dosing equation., Cancer Res, 53, 4881

10.1200/JCO.1996.14.2.399

Sinkule JA, 1984, Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors., Cancer Res, 44, 3109

Bennett CL, 1987, Phase I clinical and pharmacological study of 72‐hour continuous infusion of etoposide in patients with advanced cancer., Cancer Res, 47, 1952

10.1007/BF00686238

10.1007/BF00254537

10.1007/BF00254536

Hutson PR, 1983, Pharmacokinetics of etoposide (VP‐16) in children with refractory solid tumors (ST)., Drug Intell. Clin. Pharm, 17, 442

10.1016/S0378-4347(00)84674-5

10.1200/JCO.1995.13.12.2954

Relling MV, 1993, O‐demethylation of epipodophyllotoxins is catalyzed by a human cytochrome P450 3A4., Mol. Pharmacol, 45, 352

Fujiwara Y, 1995, Bioavailability of 50‐ and 75‐mg oral etoposide in lung cancer patients., Cancer Chemother. Pharmacol, 224, 333

10.1038/bjc.1998.385

Thông tin
Thông tin xuất bản

Pediatrics International

Tập 45 Số 1

74-79

Thông tin tác giả